| Literature DB >> 33831250 |
Brian C Brajcich1,2, Clifford Y Ko1,3,4, Jason B Liu1,5, Ryan J Ellis1,2, Michael I D Angelica6.
Abstract
Surgical site infection after pancreaticoduodenectomy is often caused by pathogens resistant to standard prophylactic antibiotics, suggesting that broad-spectrum antibiotics may be more effective prophylactic agents. This article describes the rationale and methodology underlying a multicenter randomized trial evaluating piperacillin-tazobactam compared with cefoxitin for surgical site infection prevention following pancreaticoduodenectomy. As the first US randomized surgical trial to utilize a clinical registry for data collection, this study serves as proof of concept for registry-based clinical trials.Entities:
Keywords: antibiotic prophylaxis; cefoxitin; clinical trial; pancreaticoduodenectomy; piperacillin; surgical wound infection; tazobactam drug combination
Mesh:
Substances:
Year: 2021 PMID: 33831250 PMCID: PMC8041048 DOI: 10.1002/jso.26402
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 3.454